{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:46:01Z","timestamp":1791819961886,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijid.2026.109001","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:59:03Z","timestamp":1784789943000},"page":"109001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of sex assigned at birth and HIV acquisition route on long-acting cabotegravir plus rilpivirine persistence: A real-world cohort study"],"prefix":"10.1016","volume":"171","author":[{"given":"Maria Vittoria","family":"Cossu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Oreni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Moschese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Carrozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fusetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-6219","authenticated-orcid":false,"given":"Anna Lisa","family":"Ridolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.109001_bib0001","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ijid.2026.109001_bib0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.109001_bib0003","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1097\/QAD.0000000000000782","article-title":"Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality","volume":"29","author":"Glass","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2026.109001_bib0004","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1016\/S2352-3018(25)00096-7","article-title":"Oral antiretroviral adherence interventions in the era of U=U","volume":"12","author":"Keene","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2026.109001_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/B:AIBE.0000030245.52406.bb","article-title":"Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study","volume":"8","author":"Reynolds","year":"2004","journal-title":"AIDS Behav"},{"key":"10.1016\/j.ijid.2026.109001_bib0006","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/09540120701244943","article-title":"Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa","volume":"19","author":"Hardon","year":"2007","journal-title":"AIDS Care"},{"key":"10.1016\/j.ijid.2026.109001_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111421","article-title":"A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women","volume":"9","author":"Hodgson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.109001_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108150","article-title":"A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women","volume":"9","author":"Colvin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.109001_bib0009","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/QAD.0000000000001408","article-title":"The adherence gap: a longitudinal examination of men\u2019s and women\u2019s antiretroviral therapy adherence in British Columbia, 2000-2014","volume":"31","author":"Puskas","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2026.109001_bib0010","doi-asserted-by":"crossref","first-page":"612","DOI":"10.6061\/clinics\/2013(05)06","article-title":"Gender differences in non-adherence among Brazilian patients initiating antiretroviral therapy","volume":"68","author":"de Fatima Bonolo","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ijid.2026.109001_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2334-11-86","article-title":"Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare","volume":"11","author":"Tapp","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2026.109001_bib0012","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/09540120050123774","article-title":"Barriers to antiretroviral medication adherence in HIV-infected women","volume":"12","author":"Roberts","year":"2000","journal-title":"AIDS Care"},{"key":"10.1016\/j.ijid.2026.109001_bib0013","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2026.109001_bib0014","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.109001_bib0015","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa2508228","article-title":"Cabotegravir plus rilpivirine for persons with HIV and adherence challenges","volume":"394","author":"Rana","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.109001_bib0016","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/QAD.0000000000004484","article-title":"Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort","volume":"40","author":"Troya","year":"2026","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2026.109001_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/hiv.70128","article-title":"Predictors of discontinuing injectable cabotegravir\/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy","volume":"27","author":"Faggiano","year":"2026","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2026.109001_bib0018","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/jac\/dkaf184","article-title":"Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir\/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort","volume":"80","author":"Gagliardini","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109001_bib0019","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/jac\/dkaf246","article-title":"Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead","volume":"80","author":"Buz\u00f3n-Mart\u00edn","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109001_bib0020","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/jac\/dkaf038","article-title":"Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research","volume":"80","author":"Rosas Cancio-Su\u00e1rez","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109001_bib0021","series-title":"Monitoring implementation of the Dublin Declaration on partnership to fight HIV\/AIDS in Europe and Central Asia: 2024 progress report","article-title":"HIV and migrants in the EU\/EEA","year":"2024"},{"key":"10.1016\/j.ijid.2026.109001_bib0022","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/hiv.70057","article-title":"Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: a systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV","volume":"26","author":"Ring","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2026.109001_bib0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/ph15030298","article-title":"A sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases","volume":"15","author":"Brabete","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijid.2026.109001_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.phrs.2008.07.007","article-title":"Gender differences in the treatment of HIV infection","volume":"58","author":"Floridia","year":"2008","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ijid.2026.109001_bib0025","doi-asserted-by":"crossref","first-page":"ofaf614","DOI":"10.1093\/ofid\/ofaf614","article-title":"Exploring the interaction between injection site and biological sex on the real-world population pharmacokinetics of long-acting cabotegravir and rilpivirine in people with HIV","volume":"12","author":"Tan","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.109001_bib0026","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","article-title":"Sex differences in pain: a brief review of clinical and experimental findings","volume":"111","author":"Bartley","year":"2013","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ijid.2026.109001_bib0027","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2026.109001_bib0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","article-title":"Multisite study of women living with HIV\u2019s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy","volume":"84","author":"Philbin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2026.109001_bib0029","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.109001_sbref0030","series-title":"ClinicalInfo.HIV.gov","article-title":"Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States","year":"2002"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:49:25Z","timestamp":1791816565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226006363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S1201971226006363"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109001","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of sex assigned at birth and HIV acquisition route on long-acting cabotegravir plus rilpivirine persistence: A real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"109001"}}